`
`
`
`
`
`APPLICATION NUMBER:
`22511Orig1s000
`
`
`OFFICER/EMPLOYEE LIST
`
`
`
`
`
`
`
`
`
`
`
`
`
`Officer/Employee List
`Application: NDA 022511
`
`The following officers or employees of FDA participated in the decision to approve this
`application and consented to be identified:
`
`Agarwal, Rajiv
`Bai, Jane
`Bloom, Raanan
`Brown, Raichell
`Chakder, Sushanta
`Chen, Jin
`
`Chen, Tien Mien
`Diaz, Jessica
`Fields, Ellen
`Gallo Torres, Hugo
`Griebel, Donna
`He, Ruyi
`
`Hertz, Sharon
`Holquist, Carol
`Jappar, Dilara
`Klemm, Kathleen
`Korvick, Joyce
`Lee, Sue Chih
`Malek, Khairy
`Marroum, Patrick
`Mathis, Lisa
`
`Phillips, Chantal
`Phillips, Todd
`Price, Dionne
`Purohit-Sheth, Tejashri
`Rappaport, Bob
`Sachs, Hari
`Simon, Anna
`Strongin, Brian
`Wu, Charles
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Application
`Type/Number
`--------------------
`NDA-22511
`
`Submission
`Type/Number
`--------------------
`ORIG-1
`
`Submitter Name
`
`Product Name
`
`--------------------
`POZEN INC
`
`------------------------------------------
`PN 400
`NAPROXEN/ESOMEPRAZOLE
`MAGNESIUM
`
`---------------------------------------------------------------------------------------------------------
`This is a representation of an electronic record that was signed
`electronically and this page is the manifestation of the electronic
`signature.
`---------------------------------------------------------------------------------------------------------
`/s/
`----------------------------------------------------
`
`Anna M SIMON
`05/04/2010
`
`